BridgeMD
Compares treatment options for Vulvar Lichen Sclerosus
Official title Dynamic Quadripolar Radiofrequency VS Topical Corticosteroids in Women With Vulvar Lichen Sclerosus
ClinicalTrials.gov ID: NCT07363733
What this study is testing
What is Topical high-potency corticosteroid?
Topical high-potency corticosteroid is an investigational medicine, given as a treatment applied to the skin, being studied as a potential treatment for vulvar lichen sclerosus.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a prospective, randomized study in women of reproductive age with vulvar lichen sclerosus. Participants will be randomly assigned by investigators using a computer-generated sequence to receive either combined dynamic quadripolar radiofrequency (DQRF) plus topical corticosteroid therapy or topical high-potency corticosteroid therapy alone.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 49, women only
You may be able to join if
- Women aged 18 to 49 years (women of reproductive age);
- Histologically confirmed diagnosis of vulvar lichen sclerosus;
- Written informed consent to participate in the study.
You likely can't join if
- Pregnancy or lactation;
- Malignancy at the time of treatment or during any period of follow-up;
- Postmenopausal status;
- Severe decompensated somatic disease;
- Sexually transmitted infections, including hepatitis B, hepatitis C, and syphilis;
- Presence of a cardiac pacemaker or metal-containing intrauterine device (IUD);
See the full eligibility criteria
- Women aged 18 to 49 years (women of reproductive age);
- Histologically confirmed diagnosis of vulvar lichen sclerosus;
- Written informed consent to participate in the study.
- Pregnancy or lactation;
- Malignancy at the time of treatment or during any period of follow-up;
- Postmenopausal status;
- Severe decompensated somatic disease;
- Sexually transmitted infections, including hepatitis B, hepatitis C, and syphilis;
- Presence of a cardiac pacemaker or metal-containing intrauterine device (IUD);
- History of treatment with other high-energy-based modalities within the last 6 months;
- Use of topical corticosteroids within the last 3 months;
- Immunosuppression, including immunodeficiency disorders (such as HIV/AIDS) or use of immunosuppressive medications;
- Psychiatric disorders or communication difficulties that may interfere with study participation or compliance.
The study team makes the final eligibility decision.
Where it's taking place
- Moscow, Russia
Compensation & support
A stipend or compensation may be offered.
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 49 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Moscow, Russia. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.